Compare · GUTS vs WST
GUTS vs WST
Side-by-side comparison of Fractyl Health Inc. (GUTS) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GUTS and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $23.19B, about 189.1x GUTS ($122.6M).
- WST has been more active in the news (6 items in the past 4 weeks vs 3 for GUTS).
- WST has more recent analyst coverage (18 ratings vs 6 for GUTS).
- Company
- Fractyl Health Inc.
- West Pharmaceutical Services Inc.
- Price
- -
- -
- Market cap
- $122.6M
- $23.19B
- 1M return
- -
- -3.45%
- 1Y return
- -
- +27.60%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 3
- 6
- Recent ratings
- 6
- 18
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest GUTS
- Fractyl Health to Participate in Upcoming Investor Events
- Fractyl Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation
- Director Royan Ajay bought $19,596 worth of shares (23,000 units at $0.85), increasing direct ownership by 128% to 40,901 units (SEC Form 4)
- Fractyl Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Executive Officer Rajagopalan Harith bought $18,252 worth of shares (25,000 units at $0.73), increasing direct ownership by 5% to 540,557 units (SEC Form 4)
- Director Sheffield Ian bought $25,529 worth of shares (35,000 units at $0.73) (SEC Form 4)
- SEC Form 4 filed by Director Meanwell Clive
- SEC Form 4 filed by Director Barnes Kelly Ann
- SEC Form 4 filed by Director Elia Marc
Latest WST
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Declares Quarterly Dividend
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target